In low-dose oral contraceptives containing 20 µg or 30 µg ethinylestradiol, gestodene is associated with a lower increase in coagulant factor VII than is desogestrel

Gynecological Endocrinology

Volumn 10, Issue sup2, 1996, Pages 145-148

  Bloemenkamp, K W M ^a,b   Leuven, J A Gevers ^b   Helmerhorst, F M ^a   Dersjant Roorda, M C ^a   de Boer, R ^c   Meyer, P ^b   Spielnrann, D ^d   Kluft, C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Gaubius Laboratory   (United States)

^c Department of Obstetrics and Gynecology ^*  (Netherlands)

^d Searle European Clinical R and D   (France)

Author keywords

Ethinylestradiol; Factor VII; Oral Contraceptives; Thrombosis

Indexed keywords

EID: 0008246068     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513599609045647     Document Type: Article

References (13)

1. Clinical studies with a new low-dose oral contraceptive combination, containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol. Acta Obstet. Gynecol. Sand. 1987; 144: 1 – 44
2. Bonnar J. Changes in coagulation and fibrinolysis with low dose oral contraceptives. Adv. Contracept. 1991; 7 (Suppl. 3) 285 – 91
3. Meade T. W. Risks and mechanism of cardiovascular events in users of oral contraceptives. Am. J. Obstet. Gynecol. 1988; 158: 1646
4. Inman W. H. W., Vessey M. P., Westerholm B., Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the committee on safety of drugs. Br. Med. J. 1970; 2: 203 – 9
5. Vessey M. P. Female hormones and vascular disease — an epidemiological overview. Br. J. Fam. Plann. 1980; 6: 1 – 12
6. Meade T. W., Greenburg G., Thompson S. G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30- μg estrogen preparations. Br. Med. J. 1980; 280: 1157
7. Kay C. R. Progestogens and arterial disease - evidence from the Royal College of General Practioners' study. Am. J. Obstet. Gynecol. 1982; 142: 762 – 5
8. Meade T. W., Mellows S., Brozovic M., Miller G. J., Chakrabarti R. R., North W. R. S., Haines A. P., Stirling Y., Imeson J. D., Thompson S. G. Haemostatic function and ischaemic heart disease; principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533 – 7
9. Gevers Leuven J. A., Kluft C., Dersjant-Roorda M. C., Harthoom-Lasthuizen E. J., Peters F. P.A.M.N., Bernsen M. J., Helmerhorst F. M. Changes in coagulation and fibrinolysis variables during use of two oral contraceptives containing the same dose of ethinyl estradiol and either gestodene or desogestrel. Adv. Contracept. 1990; 6: 69 – 73
10. Oswaldsson U., Wilson S., Rosén S. A simple chromogenic assay for the determination of factor VII in microtiter plates. Thromb. Haemostas. 1985; 54: 26
11. Daly L., Bonnar J. Comparative studies of 30 μg EE2 combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am. J. Obstet. Gynecol. 1990; 163: 430 – 7
12. Daume E. Influence of modem low-dose oral contraceptives on hemostasis. Adv. Contracept. 1990; 6: 51 – 68
13. Consensus Development Meeting. Aspects of oral contraceptives of relevance for cardiovascular diseases. Am. J. Obstet. Gynecol. 1990; 162: 1335 – 7